Results 221 to 230 of about 41,944 (264)

An Inducible BRCA1 Expression System with In Vivo Applicability Uncovers Activity of the Combination of ATR and PARP Inhibitors to Overcome Therapy Resistance. [PDF]

Cancers (Basel)
Irving E, Morcavallo A, Vohhodina-Tretjakova J, Wijnhoven PWG, Beckett AL, Jacques MP, Evans RS, Moss JI, Staniszewska AD, Forment JV.   +9 more
europepmc   +1 more source

Roles of ADP-Ribosyltransferases in Cancer. [PDF]

Oncol Res
Veilleux M, Nguyen A, Cao C, Shi Y.
europepmc   +1 more source

Interplay Between Poly(ADP-ribosyl)ation and Specific Inner Cellular Events That Suggest Combination Strategies for Overcoming PARP Inhibitor Resistance. [PDF]

Pharmaceutics
Xu L, Kong X, Zhang B, Ma H, Li X, Deng Y, Liu W, Ren W, Tang X, Zhang D.   +9 more
europepmc   +1 more source

Combination of PARP and KRAS^G12D inhibitors enhances therapeutic efficacy by exploiting vulnerabilities in PDAC. [PDF]

Nat Commun
Xu X, Chen X, Xu R, Huo Z, Li C, Nowsheen S, Aziz K, Yao F, Lou Z, Deng M.   +9 more
europepmc   +1 more source

Clinical application of PARP inhibitors and emerging strategies to overcome resistance: a pan-cancer perspective. [PDF]

Biomark Res
Xiang J, Li J, Guo Z, Wu J, Ma D, Xu H, Shang T, Pu P, Cong L, Zhou R, Wang X, Yu Y, Liu J.   +12 more
europepmc   +1 more source

PARP inhibition with olaparib and talazoparib for HER2-negative advanced breast cancer-Results from the prospective PRAEGNANT registry. [PDF]

NPJ Breast Cancer
Hörner M, Hartkopf A, John N, Ziegler P, Häberle L, Uhrig S, Goossens C, Amann N, Cieslik JP, Tretschock LM, Dannehl D, Deutsch TM, Dimpfl M, Ehlert M, Eichstädt K, Englisch A, Köpke MB, Krückel A, Link T, Müller A, Reinhardt K, Roth J, Schäffler H, Sych L, Tauber N, Tegeler CM, Wichmann C, Banys-Paluchowski M, Princk H, Rody A, Brucker SY, Ditsch N, Ettl J, Fehm T, Hack CC, Hadji P, Hein A, Janni WW, Kolberg HC, Lüftner D, Lux MP, Müller V, Taran FA, Tesch H, Wallwiener D, Marmé F, Seitz S, Belleville E, Michel LL, Wallwiener M, Fasching PA, Schneeweiss A, Maurer C.   +52 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Olaparib

Reactions Weekly
Reimbursement reviews of drugs later in the life cycle include a comprehensive assessment of clinical value, unmet clinical need, distinct social and ethical considerations, economic considerations, and impacts on the health systems. The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal ...
  +17 more sources

Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer

Annals of Oncology, 2022
BACKGROUND The randomized, double-blind OlympiA trial compared one year of the oral poly(adenosine diphosphate-ribose) polymerase) inhibitor, olaparib, to matching placebo as adjuvant therapy for patients with pathogenic or likely pathogenic variants in ...
Kelly-Anne Phillips
exaly   +2 more sources